Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Aberrantly methylated DNA as a biomarker in breast cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tissue inhibitor of metalloproteinases-1 as a biological marker 
in colorectal cancer: influence of smoking on plasma levels?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A simple clinical assessment is superior to systematic triage in prediction of mortality in the emergency department

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of plasma thyroxine and triiodothyronine methods on the ADVIA Centaur® XP

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gender-partitioned patient medians of serum albumin requested by general practitioners for the assessment of analytical stability

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: a pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Aberrant DNA hypermethylation at gene promoters is a frequent event in human breast cancer. Recent genome-wide studies have identified hundreds of genes that exhibit differential methylation between breast cancer cells and normal breast tissue. Due to the tumor-specific nature of DNA hypermethylation events, their use as tumor biomarkers is usually not hampered by analytical signals from normal cells, which is a general problem for existing protein tumor markers used for clinical assessment of breast cancer. There is accumulating evidence that DNA-methylation changes in breast cancer patients occur early during tumorigenesis. This may open up for effective screening, and analysis of blood or nipple aspirate may later help in diagnosing breast cancer. As a more detailed molecular characterization of different types of breast cancer becomes available, the ability to divide patients into subgroups based on DNA biomarkers may improve prognosis. Serial monitoring of DNA-methylation markers in blood during treatment may be useful, particularly when the cancer burden is below the detection level for standard imaging techniques. Overall, aberrant DNA methylation has a great potential as a versatile biomarker tool for screening, diagnosis, prognosis and monitoring of breast cancer. Standardization of methods and biomarker panels will be required to fully exploit this clinical potential.
Original languageEnglish
JournalThe International journal of biological markers
Volume28
Issue number2
Pages (from-to)141-50
Number of pages10
DOIs
Publication statusPublished - 2013

ID: 38771726